Weight Management
2
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Peptide
1100%
+ 1 programs with unclassified modality
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Sciwind BiosciencesChina - Hangzhou
1 program1
Ecnoglutide Low DosagePhase 3Peptide1 trial
Active Trials
GS
Trial Timeline
Clinical trial activity over time
2023
2024
2025
2026
Sciwind BiosciencesEcnoglutide Low Dosage
Gilead SciencesGS-4571
Clinical Trials (2)
Total enrollment: 134 patients across 2 trials
A Phase 3 Study to Evaluate the Efficacy of XW003 in Adults With Overweight or Obesity
Start: Apr 2023Est. completion: Oct 2024
Phase 3Completed
Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM)
Start: Aug 2024Est. completion: Jul 2026134 patients
Phase 1Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 134 patients
2 companies competing in this space